Lonza and Oxford Nanopore collaborate to advance mRNA Therapeutics
The significance of mRNA technology has been highlighted in recent years, particularly with its role in rapidly developing and bringing COVID-19...
2:1 for new genomic techniques
At the end of December, genetic engineering sceptics celebrated that the Council of Agriculture Ministers narrowly failed to reach a qualified...
Pierre Fabre SAS in US$31m licence deal with Kinnate Biopharma Inc
With the US$31m agreement Pierre Fabre licences the global rights to exarafenib and other pan-RAF program assets from Kinnate...
Amsilk partners with 21st.BIO
Advanced materials specialist AMSilk GmbH (Neuried, Germany) and biotech production specialst 21st.BIO (Copenhagen) have announced to join forces to...
Jazz Pharmaceuticals licences KRAS blocker from Redx Pharma
Under the term of the agreement, Redx Pharma plc (Alderley Park, UK) is to receive US$10m upfront and up to US$870m in milestone payments. Redx is...
Deregulation of new genomic techniques before decision
Although the required approval of 15 agriculture ministers was achieved in mid-December, the hotly debated proposal of the EU Commission to relax...
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...